Trade Invivyd Inc. - IVVD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.11 |
| Open | 2 |
| 1-Year Change | 88.68% |
| Day's Range | 2 - 2.06 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | 2.11 | -0.16 | -7.05% | 2.27 | 2.27 | 2.10 |
| Apr 23, 2024 | 2.24 | 0.08 | 3.70% | 2.16 | 2.36 | 2.16 |
| Apr 22, 2024 | 2.17 | -0.14 | -6.06% | 2.31 | 2.32 | 2.14 |
| Apr 19, 2024 | 2.27 | -0.07 | -2.99% | 2.34 | 2.42 | 2.24 |
| Apr 18, 2024 | 2.34 | -0.07 | -2.90% | 2.41 | 2.44 | 2.31 |
| Apr 17, 2024 | 2.46 | -0.19 | -7.17% | 2.65 | 2.70 | 2.46 |
| Apr 16, 2024 | 2.68 | -0.01 | -0.37% | 2.69 | 2.78 | 2.58 |
| Apr 15, 2024 | 2.78 | -0.10 | -3.47% | 2.88 | 2.98 | 2.73 |
| Apr 12, 2024 | 2.93 | -0.04 | -1.35% | 2.97 | 3.09 | 2.85 |
| Apr 11, 2024 | 3.03 | 0.06 | 2.02% | 2.97 | 3.11 | 2.96 |
| Apr 10, 2024 | 2.98 | -0.01 | -0.33% | 2.99 | 3.07 | 2.92 |
| Apr 9, 2024 | 2.99 | -0.07 | -2.29% | 3.06 | 3.06 | 2.90 |
| Apr 8, 2024 | 3.03 | -0.27 | -8.18% | 3.30 | 3.30 | 3.01 |
| Apr 5, 2024 | 3.27 | -0.46 | -12.33% | 3.73 | 3.91 | 3.26 |
| Apr 4, 2024 | 3.54 | -0.38 | -9.69% | 3.92 | 3.94 | 3.51 |
| Apr 3, 2024 | 3.90 | 0.09 | 2.36% | 3.81 | 4.01 | 3.81 |
| Apr 2, 2024 | 3.79 | -0.34 | -8.23% | 4.13 | 4.19 | 3.71 |
| Apr 1, 2024 | 4.24 | -0.40 | -8.62% | 4.64 | 4.69 | 4.21 |
| Mar 28, 2024 | 4.41 | 0.47 | 11.93% | 3.94 | 4.53 | 3.94 |
| Mar 27, 2024 | 3.99 | 0.30 | 8.13% | 3.69 | 4.05 | 3.63 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Invivyd Inc. Company profile
About Adagio Therapeutics Inc
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Adagio Therapeutics Inc revenues was not reported. Net loss increased from $48.1M to $143.7M. Higher net loss reflects Research and development increase from $7.3M to $110.9M (expense), Selling, general and administrative increase from $890K to $15.5M (expense), Stock-based Compensation in SGA increase from $2K to $6.3M (expense).
| Industry: | Bio Therapeutic Drugs |
1601 Trapelo Road
Suite 178
WALTHAM
MASSACHUSETTS 02451
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com